Pages that link to "Q34100488"
Jump to navigation
Jump to search
The following pages link to First-line Herceptin monotherapy in metastatic breast cancer (Q34100488):
Displaying 50 items.
- Trastuzumab-containing regimens for metastatic breast cancer (Q24194019) (← links)
- Trastuzumab containing regimens for early breast cancer (Q24200192) (← links)
- Trastuzumab containing regimens for early breast cancer (Q24244420) (← links)
- Trastuzumab containing regimens for metastatic breast cancer (Q24244565) (← links)
- ErbB2, EphrinB1, Src kinase and PTPN13 signaling complex regulates MAP kinase signaling in human cancers (Q24303562) (← links)
- A collection of breast cancer cell lines for the study of functionally distinct cancer subtypes (Q24647928) (← links)
- IgE immunotherapy against cancer (Q28081223) (← links)
- Nuclear T-STAR protein expression correlates with HER2 status, hormone receptor negativity and prolonged recurrence free survival in primary breast cancer and decreased cancer cell growth in vitro (Q30009589) (← links)
- Signal transduction of erbB receptors in trastuzumab (Herceptin) sensitive and resistant cell lines: local stimulation using magnetic microspheres as assessed by quantitative digital microscopy. (Q30798215) (← links)
- VARS2 V552V variant as prognostic marker in patients with early breast cancer (Q33587746) (← links)
- CTMP, a predictive biomarker for trastuzumab resistance in HER2-enriched breast cancer patient (Q33728102) (← links)
- Generation of an enriched pool of DNA aptamers for an HER2-overexpressing cell line selected by Cell SELEX. (Q33991887) (← links)
- Genetic instability favoring transversions associated with ErbB2-induced mammary tumorigenesis (Q34020212) (← links)
- The genetics and genomics of cancer (Q34180336) (← links)
- Comprehensive copy number profiles of breast cancer cell model genomes (Q34480698) (← links)
- Trastuzumab: a review of its use in the treatment of metastatic breast cancer overexpressing HER2. (Q34492647) (← links)
- Ixabepilone as monotherapy or in combination with capecitabine for the treatment of advanced breast cancer (Q34788890) (← links)
- Detection of HER2 amplification in circulating free DNA in patients with breast cancer. (Q34806810) (← links)
- An open-label, randomized phase II study of adecatumumab, a fully human anti-EpCAM antibody, as monotherapy in patients with metastatic breast cancer (Q34994161) (← links)
- Genetic advances will influence the practice of medicine: examples from cancer research and care of cancer patients (Q35051949) (← links)
- Enhancing the therapeutic efficacy of adenovirus in combination with biomaterials. (Q35624010) (← links)
- Platinum-based chemotherapy in metastatic breast cancer: current status. (Q35650449) (← links)
- Can maintenance trastuzumab be stopped in patients with HER2-positive metastatic breast cancer? (Q35699689) (← links)
- Monoclonal antibodies as therapeutic agents for cancer (Q35761687) (← links)
- Analysis of HER2 gene amplification using an automated fluorescence in situ hybridization signal enumeration system. (Q35789621) (← links)
- Trastuzumab for HER2-Positive Metastatic Breast Cancer: Clinical and Economic Considerations (Q35891822) (← links)
- Methodological aspects of current problems in target-based anticancer drug development (Q36540555) (← links)
- Evaluation of HER-2/neu gene amplification and protein expression in non-small cell lung carcinomas (Q36644476) (← links)
- HER2/neu overexpression in the development of muscle-invasive transitional cell carcinoma of the bladder (Q36671182) (← links)
- HER2 drives luminal breast cancer stem cells in the absence of HER2 amplification: implications for efficacy of adjuvant trastuzumab. (Q36693285) (← links)
- Phytoestrogens: perpetrators or protectors? (Q36839782) (← links)
- Targeting MDR in breast and lung cancer: discriminating its potential importance from the failure of drug resistance reversal studies. (Q36923104) (← links)
- A perspective on challenges and issues in biomarker development and drug and biomarker codevelopment (Q37411548) (← links)
- Polymalic acid nanobioconjugate for simultaneous immunostimulation and inhibition of tumor growth in HER2/neu-positive breast cancer (Q37678070) (← links)
- Current and Emerging Treatment Regimens for HER2-Positive Breast Cancer (Q37733237) (← links)
- Kinoids: a family of immunogens for active anticytokine immunotherapy applied to autoimmune diseases and cancer (Q37773243) (← links)
- The role of chemotherapy and targeted agents in patients with metastatic breast cancer (Q37937923) (← links)
- Management of elderly patients with breast cancer: updated recommendations of the International Society of Geriatric Oncology (SIOG) and European Society of Breast Cancer Specialists (EUSOMA). (Q37999119) (← links)
- Kinase dysfunction and kinase inhibitors (Q38075152) (← links)
- Systemic treatment of HER2-positive metastatic breast cancer: a systematic review. (Q38209463) (← links)
- The role of ctDNA detection and the potential of the liquid biopsy for breast cancer monitoring (Q38825179) (← links)
- Adaptive immunity programmes in breast cancer. (Q38937896) (← links)
- Trastuzumab cardiotoxicity: from clinical trials to experimental studies (Q38974785) (← links)
- Assessment of epidermal growth factor receptor (EGFR, ErbB1) and HER2 (ErbB2) protein expression levels and response to lapatinib (Tykerb, GW572016) in an expanded panel of human normal and tumour cell lines (Q40106465) (← links)
- ERBB2 phosphorylation and trastuzumab sensitivity of breast cancer cell lines. (Q40127946) (← links)
- The cost-effectiveness issue of adjuvant trastuzumab in early breast cancer (Q40303131) (← links)
- Vaccination with novel combinations of anti-HER2/neu cytokines fusion proteins and soluble protein antigen elicits a protective immune response against HER2/neu expressing tumors (Q40381044) (← links)
- HER2 signaling downregulation by trastuzumab and suppression of the PI3K/Akt pathway: an unexpected effect on TRAIL-induced apoptosis. (Q40397252) (← links)
- Radiation sensitization of human cancer cells in vivo by inhibiting the activity of PI3K using LY294002. (Q40642281) (← links)
- Marked radiographic response of a HER-2-overexpressing biliary cancer to trastuzumab (Q42033747) (← links)